Navigation Links
New monoclonal antibody inhibits tumor growth in advanced solid tumors in phase I clinical trial
Date:11/6/2012

A newly developed antibody targeting a signalling pathway that is frequently active in solid tumours has shown encouraging signs of efficacy in its first trial in humans, researchers will report at the 24th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland, today (Wednesday). [2]

A patient with advanced malignant melanoma has shown signs of tumour shrinkage and has been receiving treatment for more than 30 weeks without any serious adverse side-effects. Other patients with advanced non-small cell lung cancer (NSCLC), mesothelioma, kidney cancer and biliary tract cancer also have had extended treatments with stable disease.

The compound is a monoclonal antibody known as RG7212. It targets a soluble protein in the blood called TWEAK (Tumour Necrosis Factor (TNF)-like weak inducer of apoptosis. TWEAK binds to the receptor Fn14 (fibroblast growth factor-inducible 14) on the cell membrane, and this is the signal for a cascade of subsequent events, including activation of multiple cancer-promoting pathways. One objective of this phase I trial was to determine whether blocking of TWEAK-Fn14 signalling with RG7212 would reduce activation of these pathways.

Dr Ulrik Lassen (MD, PhD), head of the oncology phase I unit at the Rigshospitalet, Copenhagen, Denmark, will tell the Symposium: "TWEAK and Fn14 are a pair of cell signalling molecules that are part of the large family of tumour necrosis factors that play a number of roles in the development of cancer. The Fn14-receptor is over-expressed in a variety of advanced solid tumours, and signalling through TWEAK-Fn14 enhances multiple processes associated with malignancy.

"Preclinical data have shown that the RG7212 monoclonal antibody successfully targets and blocks the action of TWEAK and that it works most effectively in tumour cells where there is increased Fn14 expression. Therefore, we expected that using RG7212 to block TWEAK signalling i
'/>"/>

Contact: Emma Mason
wordmason@mac.com
ECCO-the European CanCer Organisation
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Elevated Antibody Levels May Predict Rheumatoid Arthritis Risk
2. NIH scientists map first steps in flu antibody development
3. Scientists Pinpoint Antibody That May Be Specific to MS Patients
4. Antibody therapy prevents gastrointestinal damage following radiation exposure in mice
5. Molecule found that inhibits recovery from stroke
6. Bloodstream scavenger inhibits clotting without increased bleeding
7. Laser-light testing of breast tumor fiber patterns helps show whose cancer is spreading
8. IU researchers report first effective treatment of tumors arising from common genetic disease NF1
9. Quality of Life After Cancer May Depend on Tumor Type
10. Socioeconomic disadvantage linked to breast cancer tumor disparity
11. Minorities most likely to have aggressive tumors, less likely to get radiation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , ... August 03, 2015 , ... Sutter Health’s California ... operating officer (COO) at CPMC. Hamila will start in her role effective immediately and ... , Kownacki has worked at CPMC and Sutter Health for about 15 years, including ...
(Date:8/3/2015)... ... August 03, 2015 , ... The Workgroup for Electronic ... health IT to create efficiencies in healthcare information exchange, announced the release of its ... Health and Human Services (HHS) Secretary, WEDI shared survey results and ...
(Date:8/3/2015)... ... 03, 2015 , ... Kantor & Kantor, LLP announced today ... client Rebecca Hamsher, deciding that in accordance with ERISA ( Employee Retirement Income ... treatment for bulimia, depression and other mental health problems. , According to the ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... Health notes that while an overwhelming number of Hispanics believe people can ... The overwhelming 70 percent of participants queried said making diet changes was important. ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... its industry-defining contract lifecycle management solution, as well as announced the date of ... the speed and ease of contract management tasks as well as enhancements to ...
Breaking Medicine News(10 mins):Health News:Hamila Kownacki, RN Appointed as New Chief Operating Officer at CPMC 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Novatus Unveils Milestone Software Release 2
... Feb. 6 MaxCyte, Inc., a,clinical-stage therapeutics company ... Douglas Doerfler, President & CEO, will be,presenting at ... York,Waldorf=Astoria, on Monday, February 11, 2008 at 11:45AM., ... overview and discuss the,company,s preclinical and clinical product ...
... of nevirapine greatly reduced infant infections in Africa, ... News) -- The antiretroviral drug nevirapine greatly reduces ... virus to their babies during breast-feeding, according to ... Nevirapine is already in widespread use in developing ...
... Introduces World,s First Collaborative Platform to Integrate, ... WAYLAND, Mass., Feb. 6 Tourtellotte ... for the bio-pharmaceutical industry, is,pleased to announce ... document,management and collaboration platform for complex document ...
... Inc. (Amex:,UPI), a medical device company that develops, ... of voiding dysfunction,announced today that it will be ... on Wednesday, February 20, 2008 at the Ritz ... and Medi Jiwani,Uroplasty,s Vice President and CFO, will ...
... PHILADELPHIA, Feb. 6 The much,anticipated launch ... eToims(R),Soft Tissue Comfort Center, LLC, a University ... Intramuscular,Stimulation (eToims(R) Twitch Relief Method). The site ... including back pain (the second most,common neurological ...
... well as standard, invasive method , , TUESDAY, Feb. 5 (HealthDay ... cancer has spread may be better than traditional, invasive procedures. ... of the Journal of the American Medical Association , ... era for people with lung cancer or suspected lung cancer. ...
Cached Medicine News:Health News:Drug Helps Prevent Breast-Feeding Moms From Passing on HIV 2Health News:Tourtellotte Solutions' Fusion DMC(TM) Unifies the World of Bio-Pharma Documents 2Health News:StopMusclePain.com Launched as Only Website Dedicated to Reversing Back Pain 2Health News:Less Invasive Way to Stage Lung Cancer Shows Promise 2Health News:Less Invasive Way to Stage Lung Cancer Shows Promise 3
(Date:8/3/2015)... , Aug. 3, 2015  Depomed, Inc. (NASDAQ: ... Horizon Pharma plc,s (NASDAQ: HZNP ) ("Horizon") announcement ... Directors ("Depomed Board") set a record date to determine ... The Depomed Board will review the request ... received today and contains the information required under Depomed,s ...
(Date:8/3/2015)... According to a new ... Market Study on Physiotherapy Equipment - ... 2022", the global physiotherapy equipment market is estimated to be ... and is expected to grow at a CAGR ... for US$23.7 Bn by 2022. View Full ...
(Date:8/3/2015)... , August 3, 2015 ... biotech companies, military surgical research and top-tier ... with regards to severe wound treatments for ... for regenerative medicine and tissue-engineered skin substitute ... and advancements in focus are Amarantus Bioscience ...
Breaking Medicine Technology:Depomed Comments on Horizon Pharma Announcement 2Depomed Comments on Horizon Pharma Announcement 3Depomed Comments on Horizon Pharma Announcement 4Depomed Comments on Horizon Pharma Announcement 5Depomed Comments on Horizon Pharma Announcement 6Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 3Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 6
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: